NEW YORK, Feb. 27, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on NVRO, NVCR, NUVA, and NXTM which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, the NASDAQ Composite ended the day at 7,421.46, up 1.15%; the Dow Jones Industrial Average
Redwood City, California headquartered Nevro Corp.'s stock finished Monday's session 0.68% higher at $84.35 with a total trading volume of 243,416 shares. The stock has gained 8.06% over the past three months. The Company's shares are trading above their 50-day and 200-day moving averages by 11.01% and 5.19%, respectively. Moreover, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have a Relative Strength Index (RSI) of 64.78. Get the full research report on NVRO for free by clicking below at:
Shares in NovoCure Ltd rose 7.25%, ending yesterday's session at $20.70 with a total trading volume of 1.22 million shares, which was higher than their three months average volume of 873.30 thousand shares. The stock has gained 10.11% in the previous three months and 200.00% over the past twelve months. The Company's shares are trading above their 200-day moving average by 9.98%. Moreover, shares of NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, have an RSI of 47.84.
On February 23rd, 2018, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $25 a share to $28 a share. Gain free access to the research report on NVCR at:
On Monday, San Diego, California headquartered NuVasive Inc.'s stock saw a rise of 0.77%, to close the day at $48.23. A total volume of 1.13 million shares was traded, which was higher than their three months average volume of 885.54 thousand shares. The stock is trading below its 50-day moving average by 9.13%. Additionally, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 42.56.
On February 01st, 2018, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Register for your free report coverage on NUVA at:
Shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. ended the day 3.07% higher at $24.21. A total volume of 210,281 shares was traded. The Company's shares are trading below their 50-day moving average by 1.80%. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 49.84. Get the free research report on NXTM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/medical-equipment-stocks-research-reports-released-on-nevro-novocure-nuvasive-and-nxstage-medical-300604766.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All